Join us on September 29, 2025, at the Cité Internationale Universitaire de Paris, for the NeurATRIS General Assembly Meeting!

The event is open to all. 

Registration is free but mandatory from July 15 to September 22, 2025.

-------------------------------------------------------------------------------------------------------------------------

NeurATRIS, more than 12 years of research against neurodegenerative and neurodevelopmental disorders. 

 NeurATRIS is a translational research infrastructure for innovative neuroscience therapies, unique in Europe. NeurATRIS, coordinated by CEA, is a French national research infrastructure designed to accelerate the transformation of discoveries from basic research into medical innovations for the treatment of neurodegenerative and neurodevelopmental diseases.

NeurATRIS, a distributed infrastructure, brings together several public hospitals and research institutes whose expertise and skills in neuroimaging, pharmacology and biotherapies are complementary and internationally recognized.

NeurATRIS offers a continuum of translational expertise from in vitro cell models to Phase II clinical trials: patients suffering from major brain pathologies such as Alzheimer's, Parkinson's and Huntington's diseases, multiple sclerosis, and disorders of brain development.

NeurATRIS establishes collaborations with academic and private partners, providing cutting-edge services based on a range of technological, scientific, methodological and strategic expertise that is indispensable in the value chain of translational neuroscience research activities.

NeurATRIS is the French component of the European infrastructure EATRIS-ERIC; it is also the only EATRIS infrastructure to propose a structured offer specialized in neuroscience and neurology, allowing France to position itself as a major player in this field at international and European level.

Recognized as a National Research Infrastructure in Biology and Health, NeurATRIS was established in 2012 with an initial funding of €28 million granted under the “Programme des Investissements d'Avenir”. In 2020, following an evaluation by an international committee, NeurATRIS received an additional €3.3 million in funding to support its continued development and activities through 2024.

Since 2024, the infrastructure has benefited from a dedicated allocation in the national budget, ensuring the financial resources needed for its ongoing operations in the coming years.

In parallel, as part of the France 2030 Health Innovation Plan call for projects, NeurATRIS was awarded an additional €4.8 million in 2024 to modernize its technological offerings and strengthen its capabilities in preclinical imaging, as well as in biomarker and biotherapy screening.